Evidence map›Paper›PMID 36900359›Full record

ArticleCancers2023

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru and 6 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Anti-PD-1/L1 antibody plus anti-VEGF antibodyExploration of targeted anti-tumor therapy · 2024
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takayuki TokunagaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.ORCID 0000-0002-3631-4525
Masakuni TateyamaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Yasuteru KondoSendai Kousei Hospital, 4-15 Sakamoto, Aoba-ku, Sendai City 980-0873, Miyagi, Japan.ORCID 0000-0001-5935-4346
Satoshi MiumaDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan.ORCID 0000-0003-2639-7299
Shiho MiyaseKumamoto Shinto General Hospital, 3-2-65 Ooe, Chuo-ku, Kumamoto City 862-8655, Kumamoto, Japan.
Kentaro TanakaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Satoshi NaraharaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Hiroki InadaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.ORCID 0000-0002-3456-6921
Sotaro KuranoDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Yoko YoshimaruDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Katsuya NagaokaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.ORCID 0000-0002-7152-6101
Takehisa WatanabeDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.ORCID 0000-0001-8990-9496
Hiroko SetoyamaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.
Kotaro FukubayashiKumamoto Kenhoku Hospital, 550 Tamana, Tamana City 860-0005, Kumamoto, Japan.
Motohiko TanakaPublic Health and Welfare Bureau, City of Kumamoto, 1-1 Tetori-honcho, Chuo-ku, Kumamoto City 860-8601, Kumamoto, Japan.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City 860-8556, Kumamoto, Japan.ORCID 0000-0002-2473-6966

Funding

the Kumamoto University Hospital Young Researcher Activation Project R4-13the Research Program on Hepatitis from the Japan Agency for Medical Research and Development AMED JP21fk0210048the Research Program on Hepatitis from the Japan Agency for Medical Research and Development AMED JP22fk0210103).
6 · The paper itself

Abstract

We retrospectively evaluated the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev), including the interruption or discontinuation of both Atezo and Bev, and the reduction or discontinuation of Bev, on the outcome of patients with unresectable hepatocellular carcinoma (uHCC) (median observation period: 9.40 months). One hundred uHCC from five hospitals were included. Therapeutic modifications without discontinuation of both Atezo and Bev (

Indexed as

atezolizumab plus bevacizumab therapyhepatocellular carcinomatherapeutic modifications

Identifiers

PMID36900359
PMCPMC10001232

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read80
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.